Table 2 The characteristics of the 41 patients who underwent the examinations at 4 months
Age, yrs.; mean (SD): | |
|---|---|
Total | 63.0 (11.4) |
< 65 | 21 (51) |
≥ 65 | 20 (49) |
Gender: | |
Male | 19 (46) |
Female | 22 (54) |
Primary cancer: | |
Lung, non-small-cell | 24 (59) |
Breast | 6 (15) |
Lung, small-cell | 3 (7) |
Others | 8 (19) |
KPS: | |
100–90 | 15 (37) |
80 | 14 (34) |
70 | 7 (17) |
60 | 5 (12) |
No. of brain metastases: | |
Solitary | 10 (24) |
Oligo (2–4) | 12 (29) |
Multiple (5 = <) | 14 (34) |
Meningeal carcinomatosis | 5 (12) |
GPA: | |
4.0–3.0 | 4 (10) |
2.5–2.0 | 13 (32) |
1.5–1.0 | 18 (44) |
0.5–0.0 | 6 (14) |
WBRT schedule: | |
35 Gy/14 fr | 36 (88) |
30 Gy/10 fr | 1 (2) |
Others | 4 (10) |
Treatment: | |
WBRT only | 20 (49) |
WBRT + SRS | 7 (17) |
WBRT + Surgery (+/−SRS) | 14 (34) |
Systemic therapies prior WBRT | |
No | 16 (39) |
Yes | 25 (61) |
Cytotoxic chemotherapy | 22 (54) |
Molecular targeted therapy | 11 (27) |
Hormonal therapy | 4 (10) |
Immunotherapy | 1 (2) |
Systemic therapies after WBRT | |
No | 6 (15) |
Yes | 35 (85) |
Cytotoxic chemotherapy | 19 (46) |
Molecular targeted therapy | 19 (46) |
Hormonal therapy | 2 (5) |
Immunotherapy | 3 (7) |
Intracranial control at 4 mos. | |
PD | 13 (32) |
Non-PD | 26 (63) |
Unknown | 2 (5) |